It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs
Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biot
Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.